TDP1/TOP1 ratio as a promising indicator for the response of small cell lung cancer to topotecan

Journal of Cancer Science and Therapy

Volumn 6, Issue 7, 2014, Pages 258-267

  Meisenberg, Cornelia ^a   Ward, Simon E ^b   Schmid, Peter ^b,c   El Khamisy, Sherif F ^a,d,e  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b UNIVERSITY OF SUSSEX   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e ZEWAIL CITY OF SCIENCE AND TECHNOLOGY   (Egypt)

Author keywords

Enzymatic assay; Small cell lung cancer; TDP1 protein level; TOP1 DNA; Topotecan

Indexed keywords

EID: 84906855628     PISSN: None     EISSN: 19485956     Source Type: Journal    
DOI: 10.4172/1948-5956.1000280     Document Type: Article

References (39)

1. Rosti G, Bevilacqua G, Bidoli P, Portalone L, Santo A, et al. (2006) Small cell lung cancer. Ann Oncol 17 Suppl 2: ii5-10
2. van Meerbeeck JP, Fennell DA, De Ruysscher DK (2011) Small-cell lung cancer. Lancet 378: 1741-1755.
3. Jiang J, Liang X, Zhou X, Huang L, Huang R, et al. (2010) A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. J Thorac Oncol 5: 867-873.
4. Lima JP, dos Santos LV, Sasse EC, Lima CS, Sasse AD (2010) Camptothecins compared with etoposide in combination with platinum analog in extensive stage small cell lung cancer: systematic review with meta-analysis. J Thorac Oncol 5: 1986-1993.
5. O'Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cuceviá B, et al. (2006) Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 24: 5441-5447.
6. Eckardt JR, von Pawel J, Pujol JL, Papai Z, Quoix E, et al. (2007) Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 25: 2086-2092.
7. Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow LQ, et al. (2013) Small cell lung cancer. J Natl Compr Canc Netw 11: 78-98.
8. Pommier Y, Pourquier P, Fan Y, Strumberg D (1998) Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta 1400: 83-105.
9. Wang X, Wang LK, Kingsbury WD, Johnson RK, Hecht SM (1998) Differential effects of camptothecin derivatives on topoisomerase I-mediated DNA structure modification. Biochemistry 37: 9399-9408.
10. Sordet O, Nakamura AJ, Redon CE, Pommier Y (2010) DNA double-strand breaks and ATM activation by transcription-blocking DNA lesions. Cell Cycle 9: 274-278.
11. Hudson JJR, Chiang S-C, Wells OS, Rookyard C, El-Khamisy SF (2012) SUMO modification of the neuroprotective protein TDP1 facilitates chromosomal single-strand break repair. Nature Communications 3: 733-813.
12. Alagoz M, Chiang SC, Sharma A, El-Khamisy SF (2013) ATM deficiency results in accumulation of DNA-topoisomerase I covalent intermediates in neural cells. PLoS One 8: e58239.
13. Gilbert DC, Chalmers AJ, El-Khamisy SF (2012) Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets. Br J Cancer 106: 18-24.
14. Huang S-YN, Murai J, Dalla Rosa I, Dexheimer TS, Naumova A, et al. (2013) TDP1 repairs nuclear and mitochondrial DNA damage induced by chainterminating anticancer and antiviral nucleoside analogs. Nucleic Acids Res 41:7793-7803.
15. Pommier Y, Huang SY, Gao R, Das BB, Murai J, et al. (2014) Tyrosyl-DNAphosphodiesterases (TDP1 and TDP2). DNA Repair (Amst) 19: 114-129.
16. Alagoz M, Wells OS, El-Khamisy SF (2014) TDP1 deficiency sensitizes human cells to base damage via distinct topoisomerase I and PARP mechanisms with potential applications for cancer therapy. Nucleic Acids Res 42: 3089-3103.
17. El-Khamisy SF, Saifi GM, Weinfeld M, Johansson F, Helleday T, et al. (2005) Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1. Nature 434: 108-113.
18. Chiang SC, Carroll J, El-Khamisy SF (2010) TDP1 serine 81 promotes interaction with DNA ligase IIIalpha and facilitates cell survival following DNA damage. Cell Cycle 9: 588-595.
19. Das BB, Antony S, Gupta S, Dexheimer TS, Redon CE, et al. (2009) Optimal function of the DNA repair enzyme TDP1 requires its phosphorylation by ATM and/or DNA-PK. EMBO J 28: 3667-3680.
20. Interthal H, Chen HJ, Champoux JJ (2005) Human Tdp1 cleaves a broad spectrum of substrates, including phosphoamide linkages. J Biol Chem 280: 36518-36528.
21. Walker S, Meisenberg C, Bibby RA, Askwith T, Williams G, et al. (2014) Development of an oligonucleotide-based fluorescence assay for the identification of tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitors. Anal Biochem 454: 17-22.
22. Huang SN, Pommier Y, Marchand C (2011) Tyrosyl-DNA Phosphodiesterase 1 (Tdp1) inhibitors. Expert Opin Ther Pat 21: 1285-1292.
23. Weidlich IE, Dexheimer T, Marchand C, Antony S, Pommier Y, et al. (2010) Inhibitors of human tyrosyl-DNA phospodiesterase (hTdp1) developed by virtual screening using ligand-based pharmacophores. Bioorg Med Chem 18: 182-189.
24. Marchand C, Lea WA, Jadhav A, Dexheimer TS, Austin CP, et al. (2009) Identification of phosphotyrosine mimetic inhibitors of human tyrosyl-DNA phosphodiesterase I by a novel AlphaScreen high-throughput assay. Mol Cancer Ther 8: 240-248.
25. Tomicic MT, Kaina B (2013) Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors. Biochim Biophys Acta 1835: 11-27.
26. Nitiss JL, Wang JC (1996) Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. Mol Pharmacol 50: 1095-1102.
27. Zeng Z, Sharma A, Ju L, Murai J, Umans L, et al. (2012) TDP2 promotes repair of topoisomerase I-mediated DNA damage in the absence of TDP1. Nucleic Acids Res 40: 8371-8380.
28. El-Khamisy SF (2011) To live or to die: a matter of processing damaged DNA termini in neurons. EMBO Mol Med 3: 78-88.
29. Barthelmes HU, Habermeyer M, Christensen MO, Mielke C, Interthal H, et al. (2004) TDP1 overexpression in human cells counteracts DNA damage mediated by topoisomerases I and I.I. J Biol Chem 279: 55618-55625.
30. El-Khamisy SF, Katyal S, Patel P, Ju L, McKinnon PJ, et al. (2009) Synergistic decrease of DNA single-strand break repair rates in mouse neural cells lacking both Tdp1 and aprataxin. DNA Repair (Amst) 2009;8:760-806.
31. Das BB, Huang SY, Murai J, Rehman I, Amé JC, et al. (2014) PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage. Nucleic Acids Res 42: 4435-4449.
32. Gao R, Das BB, Chatterjee R, Abaan OD, Agama K, et al. (2014) Epigenetic and genetic inactivation of tyrosyl-DNA-phosphodiesterase 1 (TDP1) in human lung cancer cells from the NCI-60 panel. DNA Repair (Amst) 13: 1-9.
33. Interthal H, Chen HJ, Kehl-Fie TE, Zotzmann J, Leppard JB, et al. (2005) SCAN1 mutant Tdp1 accumulates the enzyme--DNA intermediate and causes camptothecin hypersensitivity. EMBO J 24: 2224-2233.
34. Miao ZH, Agama K, Sordet O, Povirk L, Kohn KW, et al. (2006) Hereditary ataxia SCAN1 cells are defective for the repair of transcription-dependent topoisomerase I cleavage complexes. DNA Repair (Amst) 5: 1489-1494.
35. Pommier Y, Barcelo JM, Rao VA, Sordet O, Jobson AG, et al. (2006) Repair of topoisomerase I-mediated DNA damage. Prog Nucleic Acid Res Mol Biol 81: 179-229.
36. Alagoz M, Gilbert DC, El-Khamisy S, Chalmers AJ (2012) DNA repair and resistance to topoisomerase I inhibitors: mechanisms, biomarkers and therapeutic targets. Curr Med Chem 19: 3874-3885.
37. Hamilton NK, Maizels N (2010) MRE11 function in response to topoisomerase poisons is independent of its function in double-strand break repair in Saccharomyces cerevisiae. PLoS One 5: e15387.
38. Deng C, Brown JA, You D, Brown JM (2005) Multiple endonucleases function to repair covalent topoisomerase I complexes in Saccharomyces cerevisiae. Genetics 170: 591-600.
39. Vance JR, Wilson TE (2002) Yeast Tdp1 and Rad1-Rad10 function as redundant pathways for repairing Top1 replicative damage. Proc Natl Acad Sci U S A 99: 13669-13674.